Risultati per: Melanoma cutaneo

Introduction
Three-dimensional (3D) total body photography may improve early detection of melanoma and facilitate surveillance, leading to better prognosis and lower healthcare costs. The Australian Centre of Excellence in Melanoma Imaging and Diagnosis (ACEMID) cohort study will assess long-term outcomes from delivery of a precision strategy of monitoring skin lesions using skin surface imaging technology embedded into health services across Australia.

Methods and analysis
A prospective cohort study will enrol 15 000 participants aged 18 years and above, across 15 Australian sites. Participants will attend study visits according to their melanoma risk category: very high risk, high risk or low/average risk, every 6, 12 and 24 months, respectively, over 3 years. Participants will undergo 3D total body photography and dermoscopy imaging at study visits. A baseline questionnaire will be administered to collect sociodemographic, phenotypic, quality of life and sun behaviour data. A follow-up questionnaire will be administered every 12 months to obtain changes in sun behaviour and quality of life. A saliva sample will be collected at the baseline visit from a subsample.

Ethics and dissemination
The ACEMID cohort study was approved by the Metro South Health Human Research Ethics Committee (approval number: HREC/2019/QMS/57206) and the University of Queensland Human Research Ethics Committee (approval number: 2019003077). The findings will be reported through peer-reviewed and lay publications and presentations at conferences.

Trial registration number
ACTRN12619001706167.

This cohort study investigates patterns in melanoma detection in racial and ethnic minority populations as part of a large, primary care–based screening initiative.

L’ateneo di Trieste nello studio pubblicato su Nature Medicine

This nonrandomized clinical trial examines the activity and safety of camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma.

In this issue of JAMA Dermatology, Patel and colleagues examine mortality after a diagnosis of melanoma in situ. Melanoma in situ is the earliest stage of melanoma (stage 0) and is localized to the outermost layer of skin (epidermis). It is regarded as a potential precursor lesion to invasive melanoma (stages I to IV), in which melanoma invades the deeper layers of the skin and, in doing so, acquires the potential ability to spread to distant sites, which may ultimately lead to death from melanoma. Nevertheless, melanoma in situ is not an obligate precursor of invasive melanoma, and it is increasingly acknowledged that some lesions diagnosed as melanoma are clinically indolent and will never progress. The latter scenario is often referred to as overdiagnosis of melanoma.

This cohort study examines mortality and factors associated with mortality after a diagnosis of melanoma in situ.

This cohort study compares outcomes associated with wide- vs narrow-margin excisions in patients with T1a melanoma near critical structures.

This consensus statement provides consensus recommendations on optimal screening practices and prebiopsy diagnostic, postbiopsy diagnostic, and prognostic assessment of cutaneous melanoma.

This cohort study examines the association between habitual diet and response to treatment with immune checkpoint blockade among patients with advanced melanoma.

Melanoma mortality has declined over the past decade, largely due to availability of dramatically more effective treatments of advanced disease, but melanoma remains an important public health problem due to a persistent significant mortality risk as well as morbidity and cost. In this issue, Kashani-Sabet et al report early detection and prognostic assessment recommendations of a large group of experts using a modified Delphi approach. We consider these recommendations from 3 perspectives: the role of risk stratification, the role of gene expression profiling (GEP), and the hierarchy of evidence as it pertains to public health.

Studio Moderna e Merck,sfrutta tecnologia a mRNA usata per Covid

To the Editor We read with tremendous enthusiasm the original investigation by Dr Adamson and colleagues demonstrating the prominence of high diagnostic scrutiny in melanoma incidence and the necessity to take seriously the role it plays in melanoma mortality. What intrigued us is the study’s conclusion that UV radiation exposure has a weak association with melanoma incidence in the US, shattering the long-standing perception of UV radiation as a formidable risk factor. If the conclusion holds true, it will alleviate the unease to some extent and downsize the magnitude of risk factors, among which UV radiation has been the most widely accepted and biggest culprit for melanoma.

This scoping review describes strategies to improve adherence to self-management practices in randomized clinical trials of people at high risk of melanoma.